Skip to main content
Intended for healthcare professionals
Restricted access
Research article
First published online July 11, 2016

Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA

Abstract

Objective

We investigated the agreement between the tuberculin skin test (TST) and the QuantiFERON-TB gold (QFT-G) assay in the diagnosis of latent tuberculosis infection (LTBI) in patients with systemic lupus erythematosus (SLE). Furthermore, we evaluated the factors associated with indeterminate results in the QFT-G assay in patients with SLE.

Methods

We enrolled 136 patients with SLE prospectively, and compared them to 66 patients with rheumatoid arthritis (RA). In addition to the TST, QFT-G assay, patients’ medications, and Bacillus Calmette-Guérin (BCG) vaccination status were also investigated. A positive TST or QFT-G assay result without an active tuberculosis lesion on chest x-ray was considered to indicate a diagnosis of LTBI.

Results

The prevalence of LTBI was 26.5% in patients with SLE and 30.3% in patients with RA. The agreement between the TST and QFT-G assay was fair in SLE patients, but poor in RA patients. BCG vaccination was one factor associated with discordance between TST and QFT-G. Older age and higher SLE Disease Activity Index (SLEDAI) score were associated with a negative TST/positive QFT-G result in patients with SLE. Higher SLEDAI score and increased glucocorticoid dose were associated with an indeterminate result in the QFT-G assay for patients with SLE.

Conclusions

Agreement between the QFT-G assay and TST in patients with SLE was found to be fair. However, BCG vaccination status, age, and SLEDAI score are all factors that could result in discordance between the two tests. Indeterminate results from the QFT-G assay may be caused by a higher SLEDAI score or increased glucocorticoid dose.

Get full access to this article

View all access and purchase options for this article.

References

1. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003; 15: 528–534.
2. Doria A, Canova M, Tonon M, et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 2008; 8: 24–28.
3. Wang Z, Wang Y, Zhu R, et al. Long-term survival and death causes of systemic lupus erythematosus in China: A systemic review of observational studies. Medicine (Baltimore) 2015; 94: e794–e794.
4. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity 2005; 38: 473–485.
5. Yun JE, Lee SW, Kim TH, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 2002; 20: 127–132.
6. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998; 16: 9–13.
7. World Health Organization. Global tuberculosis control: Epidemiology, strategy, financing. WHO report, 2015. Geneva: World Health Organization.
8. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008; 8: 147–152.
9. Ildirim I, Hacimustafaoglu M, Ediz B. Correlation of tuberculin induration with the number of Bacillus Calmette-Guerin vaccines. Pediatr Infect Dis J 1995; 14: 1060–1063.
10. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: What is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192–1204.
11. Choi CM, Kang CI, Kim DH, et al. The role of TST in the diagnosis of latent tuberculosis infection among military personnel in South Korea. Int J Tuberc Lung Dis 2006; 10: 1342–1346.
12. Wang L, Turner MO, Elwood RK, et al. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002; 57: 804–809.
13. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360–1361.
14. Pascual-Ramos V, Hernandez-Cruz B, Villalobos I, et al. Purified protein derivative reaction in systemic lupus erythematosus patients. Indirect study of cellular immunity. Lupus 2002; 11: 25–30.
15. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep 2010; 59(RR-5): 1–25.
16. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: A systematic review and meta-analysis. Eur Respir J 2011; 37: 88–99.
17. Kim JH, Cho SK, Han M, et al. Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases. Semin Arthritis Rheum 2013; 42: 424–432.
18. Lee JH, Sohn HS, Chun JH, et al. Poor agreement between QuantiFERON-TB Gold test and tuberculin skin test results for the diagnosis of latent tuberculosis infection in rheumatoid arthritis patients and healthy controls. Korean J Intern Med 2014; 29: 76–84.
19. Yilmaz N, Zehra Aydin S, Inanc N, et al. Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent Mycobacterium tuberculosis infection in lupus patients. Lupus 2012; 21: 491–495.
20. Arenas Miras Mdel M, Hidalgo-Tenorio C, Jimenez-Gamiz P, et al. Diagnosis of latent tuberculosis in patients with systemic lupus erythematosus: T.SPOT.TB versus tuberculin skin test. Biomed Res Int 2014; Article ID 291031.
21. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005; 293: 2756–2761.
22. Takeda N, Nojima T, Terao C, et al. Interferon-gamma release assay for diagnosing Mycobacterium tuberculosis infections in patients with systemic lupus erythematosus. Lupus 2011; 20: 792–800.
23. Jung HJ, Kim TJ, Kim HS, et al. Analysis of predictors influencing indeterminate whole-blood interferon-gamma release assay results in patients with rheumatic diseases. Rheumatol Int 2014; 34: 1711–1720.
24. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: A metaanalysis. Chest 2010; 137: 952–968.
25. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.
26. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–324.
27. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J 2010; 36: 1185–1206.
28. Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54: 49–55.
29. Jung YJ, Woo HI, Jeon K, et al. The significance of sensitive interferon gamma release assays for diagnosis of latent tuberculosis infection in patients receiving tumor necrosis factor-alpha antagonist therapy. PLoS One 2015; 10: e0141033–e0141033.
30. Chang B, Park HY, Jeon K, et al. Interferon-gamma release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol 2011; 30: 1535–1541.
31. Lee H, Park HY, Jeon K, et al. QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment. PLoS One 2015; 10: e0119260–e0119260.
32. Korea Centers for Disease Control and Prevention. Available at: www.lungkorea.org/thesis/file/korean_guidelines_for_tuberculosis_2014.pdf (accessed 22 December, 2014).
33. Mehta B, Zapantis E, Petryna O, et al. Screening optimization of latent tuberculosis infection in rheumatoid arthritis patients. Arthritis 2015; Article ID 569620.
34. Kim EY, Lim JE, Jung JY, et al. Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 2009; 9: 207–207.
35. Tamborenea MN, Tate G, Mysler E, et al. Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Rheumatol Int 2010; 30: 613–616.
36. Lee E, Holzman RS. Evolution and current use of the tuberculin test. Clin Infect Dis 2002; 34: 365–370.
37. Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009; 33: 586–593.
38. Pratt A, Nicholl K, Kay L. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: The Newcastle (UK) experience. Rheumatology (Oxford) 2007; 46: 1035–1036.
39. Maeda T, Banno S, Maeda S, et al. Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: Proposal to decrease the lower cutoff level for assessing latent tuberculosis infection. Mod Rheumatol 2010; 20: 18–23.
40. Behar SM, Shin DS, Maier A, et al. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol 2009; 36: 546–551.
41. Cobanoglu N, Ozcelik U, Kalyoncu U, et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 2007; 11: 1177–1182.
42. La Cava A. Lupus and T cells. Lupus 2009; 18: 196–201.
43. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 2006; 63: 60–72.

Cite article

Cite article

Cite article

OR

Download to reference manager

If you have citation software installed, you can download article citation data to the citation manager of your choice

Share options

Share

Share this article

Share with email
EMAIL ARTICLE LINK
Share on social media

Share access to this article

Sharing links are not relevant where the article is open access and not available if you do not have a subscription.

For more information view the SAGE Journals article sharing page.

Information, rights and permissions

Information

Published In

Pages: 1341 - 1348
Article first published online: July 11, 2016
Issue published: October 2016

Keywords

  1. QuantiFERON-TB Gold
  2. tuberculin skin test
  3. latent tuberculosis infection
  4. systemic lupus erythematosus

Rights and permissions

© The Author(s) 2016.
Request permissions for this article.

History

Manuscript received: January 6, 2016
Manuscript accepted: February 23, 2016
Published online: March 15, 2016
Published OnlineFirst: July 11, 2016
Issue published: October 2016
PubMed: 26985011

Authors

Affiliations

Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea

Notes

Hyoun-Ah Kim, Assistant Professor, Department of Rheumatology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon, 443-380, Korea. Email: [email protected]

Metrics and citations

Metrics

Journals metrics

This article was published in Lupus.

VIEW ALL JOURNAL METRICS

Article usage*

Total views and downloads: 298

*Article usage tracking started in December 2016

Altmetric

See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores


Articles citing this one

Web of Science: 12 view articles Opens in new tab

Crossref: 12

  1. 2022 EULAR recommendations for screening and prophylaxis of chronic an...
    Go to citation Crossref Google Scholar
  2. Systematic literature review informing the 2022 EULAR recommendations ...
    Go to citation Crossref Google Scholar
  3. High prevalence of latent tuberculosis using the QuantiFERON-TB Gold P...
    Go to citation Crossref Google Scholar
  4. Host factors associated to false negative and indeterminate results in...
    Go to citation Crossref Google Scholar
  5. <p>Activity Disease in SLE Patients Affected IFN-γ in the IGRA Results...
    Go to citation Crossref Google Scholar
  6. First case of pleural amyloidosis in systemic erythematosus: report an...
    Go to citation Crossref Google Scholar
  7. The interplay between tuberculosis and systemic lupus erythematosus
    Go to citation Crossref Google Scholar
  8. IGRA testing in patients with immune-mediated inflammatory diseases: w...
    Go to citation Crossref Google Scholar
  9. Interferon-gamma release assay for the diagnosis of latent tuberculosi...
    Go to citation Crossref Google Scholar
  10. Mycobacterium tuberculosis infection in systemic lupus erythematosus p...
    Go to citation Crossref Google Scholar
  11. Unique Chemokine Profiles of Lung Tissues Distinguish Post-chemotherap...
    Go to citation Crossref Google Scholar
  12. Infection in systemic lupus erythematosus, similarities, and differenc...
    Go to citation Crossref Google Scholar

Figures and tables

Figures & Media

Tables

View Options

Get access

Access options

If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:


Alternatively, view purchase options below:

Purchase 24 hour online access to view and download content.

Access journal content via a DeepDyve subscription or find out more about this option.

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text